AbCellera Biologics (ABCL) PT Lowered to $32 at BMO Capital
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $11.48 --0%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 18
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 18
Join SI Premium – FREE
BMO Capital analyst Gary Nachman lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $32.00 (from $40.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
- Toyo Suisan Kaisha Ltd. (2875:JP) (TSUKF) PT Raised to JPY13,400 at JPMorgan
- Air New Zealand Limited (AIR:NZ) (ANZFF) PT Lowered to NZD0.38 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
